Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/23/2867498/0/en/Revive-Therapeutics-Announces-Type-C-Meeting-Request-Granted-by-FDA-for-Clinical-Study-of-Bucillamine-to-Treat-Long-COVID.html
https://www.globenewswire.com/news-release/2024/04/18/2865256/0/en/Revive-Therapeutics-Announces-FDA-Acceptance-of-Meeting-Request-for-Long-COVID-Diagnostic-Product.html
https://www.globenewswire.com/news-release/2024/04/02/2855836/0/en/Revive-Therapeutics-Provides-Update-on-Psilocybin-Clinical-Study-for-Methamphetamine-Use-Disorder.html
https://www.globenewswire.com/news-release/2024/03/27/2853251/0/en/Revive-Therapeutics-Submits-Type-C-Meeting-Request-Package-to-FDA-for-Clinical-Study-of-Bucillamine-to-Treat-Long-COVID.html
https://www.globenewswire.com/news-release/2024/03/19/2848420/0/en/Revive-Therapeutics-To-Submit-Type-C-Meeting-Request-with-FDA-for-Bucillamine-to-Treat-Long-COVID.html
https://www.globenewswire.com//news-release/2024/03/12/2844382/0/en/Revive-Therapeutics-Provides-Corporate-Update.html
https://www.globenewswire.com//news-release/2024/02/26/2835487/0/en/Revive-Therapeutics-Ltd-Announces-Closing-of-the-Second-and-Final-Tranche-of-Its-Private-Placement-for-Gross-Proceeds-of-1-187-110.html
https://www.globenewswire.com//news-release/2024/02/01/2821891/0/en/Revive-Therapeutics-Explores-the-Use-of-Bucillamine-for-Long-COVID.html
https://www.globenewswire.com/news-release/2024/01/31/2821606/0/en/Revive-Therapeutics-Ltd-Announces-Closing-of-the-First-Tranche-of-Its-Private-Placement-for-Gross-Proceeds-of-913-500.html
https://www.globenewswire.com//news-release/2024/01/24/2816162/0/en/Revive-Therapeutics-Ltd-Announces-Offering-of-Up-to-3-Million.html